<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123950</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-8HX</org_study_id>
    <nct_id>NCT05123950</nct_id>
  </id_info>
  <brief_title>A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe</brief_title>
  <official_title>Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Patients in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to collect real-world data that describes&#xD;
      treatment patterns and clinical outcomes in participants with first line recurrent/metastatic&#xD;
      squamous cell carcinoma of the head &amp; neck (1L R/M SCCHN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">March 19, 2021</completion_date>
  <primary_completion_date type="Actual">March 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Age</measure>
    <time_frame>At Baseline</time_frame>
    <description>Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head &amp; Neck (SCCHN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Height</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Weight</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Body surface area (BSA)</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Health insurance coverage</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Tobacco use</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Patient comorbidities</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Alcohol use</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Human papillomavirus(HPV) p -16 status</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Date of early stage diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Receive a platinum-based agent for early stage diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Receive radiation within 6 months prior to early stage diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Undergo related surgeries within 6 months prior to early stage diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Date of R/M SCCHN diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Specialty of diagnosing physician</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Primary site of SCCHN at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Clinical stage at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Primary tumor stage at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Lymph node involvement at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Metastasis at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Histologic tumor grade at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Overall prognosis at R/M diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of 1L R/M SCCHN participants treated with nivolumab: Platinum-based grouping</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of diagnostic procedures of 1L R/M SCCHN participants treated with nivolumab</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: First (second, third+) Line of therapy (LOT)</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Duration of LOT</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Administration form</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Dose</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Dose changes</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Frequency of treatment regimen</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Schedule of agent administration</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Number of planned cycles</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Number of completed cycles</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Reasons for prescribing therapy</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Reasons for discontinuing therapy</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Dose delays</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Radiation performed for R/M disease</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of treatment patterns of 1L R/M SCCHN participants treated with nivolumab: Surgical procedures performed for R/M disease</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of adverse events of 1L R/M SCCHN participants treated with nivolumab</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of adverse events of 1L R/M SCCHN participants treated with nivolumab: Action taken</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of adverse events of 1L R/M SCCHN participants treated with nivolumab: Resolution</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical outcomes of 1L R/M SCCHN participants treated with nivolumab: Response to therapy</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical outcomes of 1L R/M SCCHN participants treated with nivolumab: Duration of response</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical outcomes of 1L R/M SCCHN participants treated with nivolumab: Overall survival</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical outcomes of 1L R/M SCCHN participants treated with nivolumab: Progression free survival</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient demographics, clinical characteristics, and treatment patterns between the Cohort 1- Augment and Cohort 1</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of time to event endpoints of OS, PFS, and DOR between Cohort 1- Augment and Cohort 1</measure>
    <time_frame>Up to approximately 36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">304</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Participants diagnosed with R/M SCCHN between 01-Jan-2014 and 31-Dec-2016</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1- Augment</arm_group_label>
    <description>Participants newly initiating 1L treatment for R/M SCCHN between 01-Jun-2017 and 01-Jun-2018</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A population of participants diagnosed with Recurrent/Metastatic Squamous cell carcinoma of&#xD;
        the head and neck (R/M SCCHN) and treated with 1L therapy in two cohorts based on time&#xD;
        period of initiating 1L treatment. Patients will be enrolled from France (FR), Germany&#xD;
        (DE), and the United Kingdom (UK).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Participants are included in Cohort 1 - Augment if they meet the following criteria:&#xD;
&#xD;
          -  Adults18 years or older&#xD;
&#xD;
          -  Diagnosis of histologically confirmed R/M SCCHN, from any of the following primary&#xD;
             sites only: oral cavity, oropharynx, hypopharynx, and larynx between 01-Jun-2017 and&#xD;
             31-June-2018.&#xD;
&#xD;
          -  Prescribed 1L treatment for R/M SCCHN&#xD;
&#xD;
          -  Treatment history and response available for medical chart abstraction from date of&#xD;
             diagnosis until death or the end of the study in living participants&#xD;
&#xD;
          -  Have available for review one month of follow-up data available post initiation of 1L&#xD;
             R/M SCCHN therapy&#xD;
&#xD;
          -  Informed consent form (ICF) signature/collection of living participants, as required&#xD;
             by country regulation and local ethics committees&#xD;
&#xD;
        Participants are included in Cohort 1 if they meet the following criteria:&#xD;
&#xD;
          -  Adults 18 years or older&#xD;
&#xD;
          -  Diagnosis of histologically confirmed R/M SCCHN, from any of the following primary&#xD;
             sites only: oral cavity, oropharynx, hypopharynx and larynx between 01-Jan-2014 and&#xD;
             31-Dec-2016.&#xD;
&#xD;
          -  Prescribed 1L treatment for R/M SCCHN&#xD;
&#xD;
          -  Treatment history and response available for medical chart abstraction from the date&#xD;
             of diagnosis until death or the end of the study in living participants&#xD;
&#xD;
          -  Have available for review one month of follow-up data post initiation of 1L R/M SCCHN&#xD;
             therapy&#xD;
&#xD;
          -  Informed consent form (ICF) signature/collection of living participants, as required&#xD;
             by country regulation and local ethics committees&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants were excluded from either cohort if they meet the following criteria:&#xD;
&#xD;
          -  Were enrolled in a cancer treatment-related clinical trial since the diagnosis of R/M&#xD;
             SCCHN&#xD;
&#xD;
          -  Recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of&#xD;
             unknown primary site, squamous cell carcinoma that originated from the skin and&#xD;
             salivary gland or non-squamous histologies (e.g., mucosal melanoma).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Data Analytics</name>
      <address>
        <city>Parsippany</city>
        <state>New Jersey</state>
        <zip>07054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Recurrent</keyword>
  <keyword>SCCHN</keyword>
  <keyword>Treatment patterns</keyword>
  <keyword>Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

